BridgeMD
New treatment option for Extracorporeal Membrane Oxygenation Complication
Official title Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO
ClinicalTrials.gov ID: NCT06276010
What this study is testing
What is nafamostat mesilate?
nafamostat mesilate is an investigational medicine, being studied as a potential treatment for extracorporeal membrane oxygenation complication.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years old
- VA-ECMO or VV-ECMO was accepted after cardiac surgery.
- The ECMO treatment team believes that systemic anticoagulation is needed
- Sign the informed consent form
You likely can't join if
- The researchers believe that there are other causes of active bleeding that are not suitable to participate in this study.
- Long-term use of anticoagulants before establishment of ECMO
- Antiplatelet drugs were used before the establishment of ECMO
- Severe liver insufficiency
- Connective tissue disease
- There is a history of allergy to heparin or nemolastat mesylate.
See the full eligibility criteria
- Age ≥ 18 years old
- VA-ECMO or VV-ECMO was accepted after cardiac surgery.
- The ECMO treatment team believes that systemic anticoagulation is needed
- Sign the informed consent form
- The researchers believe that there are other causes of active bleeding that are not suitable to participate in this study.
- Long-term use of anticoagulants before establishment of ECMO
- Antiplatelet drugs were used before the establishment of ECMO
- Severe liver insufficiency
- Connective tissue disease
- There is a history of allergy to heparin or nemolastat mesylate.
- Pregnant
- Previous diagnosis of heparin-induced thrombocytopenia
- Expect to die within 48 hours
- ECPR
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.